Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Manja Wobus, PhD, Anna Mies, Valentina Magno, PhD, Cindy Welzel, Susann Winter, PhD, Friedrich Stoelzel, MD, Carsten Werner, PhD, Martin Bornhaeuser, MD, Uwe Platzbecker, MD

Blood (2019) 134 (Supplement_1): 1699.

https://doi.org/10.1182/blood-2019-129814

Published: 2019

Journal Articles

Canonical Signaling By TGF Family Members in Mesenchymal Stromal Cells Is Dispensable for Hematopoietic Niche Maintenance Under Basal and Stress Conditions

Joseph R. Krambs, BS, Grazia Abou Ezzi, PhD, Juo-Chin Yao, Justin T. Li, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 1209.

https://doi.org/10.1182/blood-2019-128693

Published: 2019

Journal Articles

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Erica Dander, PhD, Federica Portale, PhD, Daniela Silvestri, Giulia Cricrì, Silvia Bresolin, PhD, Stefania Gaspari, Barbara Russo, Monica Lupi, Paolo Ubezio, Geertruy te Kronnie, Maria Grazia Valsecchi, PhD, Franco Locatelli, Carmelo Rizzari, MD, Andrea Biondi, MD, Giovanna D'Amico, BSc, PhD MSc

Blood (2018) 132 (Supplement 1): 1296.

https://doi.org/10.1182/blood-2018-99-116668

Published: 2018

Journal Articles

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

Manja Wobus, Anna Mies, Nandini Asokan, Uta Oelschlaegel, Susann Winter, Martina Rauner, PhD, Lorenz Hofbauer, Martin Bornhäuser, Uwe Platzbecker

Blood (2018) 132 (Supplement 1): 939.

https://doi.org/10.1182/blood-2018-99-114536

Published: 2018

Journal Articles

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Blood (2018) 132 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2018-99-111770

Published: 2018

Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 255.

https://doi.org/10.1182/blood.V130.Suppl_1.255.255

Published: 2017

Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD

Blood (2017) 130 (Supplement 1): 2982.

https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982

Published: 2017

Journal Articles

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 5551.

https://doi.org/10.1182/blood.V128.22.5551.5551

Published: 2016

Journal Articles

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Elias J. Jabbour, MD, Allison Pike, RN, Kate J Newberry, PhD, Lingsha Zhou, Sherry Pierce, BSN, BA, Xuemei Wang, MS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 478.

https://doi.org/10.1182/blood.V128.22.478.478

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

Journal Articles

Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS

Paraskevi Rea Oikonomidou, MD, Ping La, PhD, Ritama Gupta, MSc, Vania Lo Presti, Carla Casu, PhD, Laura Breda, PhD, Deborah Watson, PhD, Rajasekhar NVS Suragani, PhD, Ravindra Kumar, PhD, Stefano Rivella, PhD

Blood (2016) 128 (22): 2439.

https://doi.org/10.1182/blood.V128.22.2439.2439

Published: 2016

Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 92.

https://doi.org/10.1182/blood.V126.23.92.92

Published: 2015

Journal Articles

Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia

Pedro A. Martinez, PhD, Rajasekhar NVS Suragani, PhD, Manoj Bhasin, PhD, Robert Li, Robert Scott Pearsall, PhD, Ravindra Kumar, PhD

Blood (2015) 126 (23): 751.

https://doi.org/10.1182/blood.V126.23.751.751

Published: 2015

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Goetze, MD, Philipp Kiewe, MD, Karin Mayer, MD, Oliver Ottman, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 411.

https://doi.org/10.1182/blood.V124.21.411.411

Published: 2014

Journal Articles

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio G. Piga, MD, Silverio Perrotta, MD, Angela Melpignano, MD, Caterina Borgna-Pignatti, MD, Ersi Voskaridou, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Yesim Aydinok, MD, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 53.

https://doi.org/10.1182/blood.V124.21.53.53

Published: 2014

Journal Articles

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Rajasekhar N. V. S. Suragani, Sharon M. Cawley, Robert Li, Samantha Wallner, Mark J. Alexander, Aaron W. Mulivor, Sara Gardenghi, Stefano Rivella, Asya V. Grinberg, R. Scott Pearsall, Ravindra Kumar

Blood (2014) 123 (25): 3864–3872.

https://doi.org/10.1182/blood-2013-06-511238

Published: 2014

Includes: Supplemental data

Journal Articles

Sotatercept, An Activin Receptor-2a Ligand Trap, Modulates Hepcidin Levels In Primary Human Hepatocytes

Mehnaz Malek, Carla Heise, PhD, Rajesh Chopra, PhD, Tom O Daniel, MD, PhD, Victoria Sung, PhD

Blood (2013) 122 (21): 3441.

https://doi.org/10.1182/blood.V122.21.3441.3441

Published: 2013

NARROW

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Canonical Signaling By TGF Family Members in Mesenchymal Stromal Cells Is Dispensable for Hematopoietic Niche Maintenance Under Basal and Stress Conditions

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Sotatercept, An Activin Receptor-2a Ligand Trap, Modulates Hepcidin Levels In Primary Human Hepatocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only